Upstream Bio successfully transitioned into a publicly traded clinical-stage biopharmaceutical corporation via its initial public offering on the Nasdaq exchange, focusing its corporate milestones on advancing its lead therapeutic candidate, verekitug, through extensive clinical trials targeting severe respiratory and inflammatory diseases.